GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.66 MXN | -1.88% |
|
+2.21% | +17.66% |
Presentation Operator MessageOperator (Operator)Greetings, ladies and gentlemen, thank you for...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Sector
Pharmaceuticals
Calendar
2024-07-23
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
16.66
MXN
Average target price
20.6
MXN
Spread / Average Target
+23.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.66% | 910M | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| -3.40% | 157B |
- Stock Market
- Equities
- LAB B Stock
- News Genomma Lab Internacional, S.A.B. de C.V.
- Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q2 2022 Earnings Call, Jul 28, 2022
